259 related articles for article (PubMed ID: 21999254)
1. Welcome to the World Stem Cell Report.
Siegel B
Regen Med; 2011 Nov; 6(6 Suppl):1-2. PubMed ID: 21999254
[No Abstract] [Full Text] [Related]
2. Global update: Germany.
Lauter FR; Wirsching S
Regen Med; 2011 Nov; 6(6 Suppl):154-7. PubMed ID: 21999280
[TBL] [Abstract][Full Text] [Related]
3. The World Stem Cell Summit. Interview with Bernard Siegel.
Siegel B
Regen Med; 2011 Nov; 6(6 Suppl):109-12. PubMed ID: 21999271
[TBL] [Abstract][Full Text] [Related]
4. Promoting justice in stem cell intellectual property.
Regenberg A; Mathews DJ
Regen Med; 2011 Nov; 6(6 Suppl):79-84. PubMed ID: 21999266
[TBL] [Abstract][Full Text] [Related]
5. Making stem cells count for global health.
McMahon DS; Thorsteinsdóttir H
Regen Med; 2011 Nov; 6(6 Suppl):163-6. PubMed ID: 21999282
[TBL] [Abstract][Full Text] [Related]
6. Trends in the stem cell and regenerative medicine industry.
Ilic D
Regen Med; 2012 Sep; 7(5):645-8. PubMed ID: 22954435
[TBL] [Abstract][Full Text] [Related]
7. Global update: Scotland.
Courtney A
Regen Med; 2011 Nov; 6(6 Suppl):150-2. PubMed ID: 21999279
[TBL] [Abstract][Full Text] [Related]
8. Geron's quixotic fate.
Scott C; Huggett B
Nat Biotechnol; 2012 Jun; 30(6):497. PubMed ID: 22678383
[No Abstract] [Full Text] [Related]
9. State stem cell agency floats idea of $70 million 'Alpha' clinics.
Dolgin E
Nat Med; 2013 Jul; 19(7):798. PubMed ID: 23836206
[No Abstract] [Full Text] [Related]
10. Global update: Japan.
Sipp D
Regen Med; 2011 Nov; 6(6 Suppl):160-2. PubMed ID: 21999281
[TBL] [Abstract][Full Text] [Related]
11. Stem cells: intellectual property issues in regenerative medicine.
Zachariades NA
Stem Cells Dev; 2013 Dec; 22 Suppl 1(Suppl 1):59-62. PubMed ID: 24304078
[TBL] [Abstract][Full Text] [Related]
12. Stem cell research in Latin America: update, challenges and opportunities in a priority research area.
Palma V; Pitossi FJ; Rehen SK; Touriño C; Velasco I
Regen Med; 2015; 10(6):785-98. PubMed ID: 26440367
[TBL] [Abstract][Full Text] [Related]
13. California: 'the Stem Cell State'. Interview with Jonathan Thomas.
Thomas J
Regen Med; 2011 Nov; 6(6 Suppl):113-5. PubMed ID: 21999272
[TBL] [Abstract][Full Text] [Related]
14. Stem cells: the 3-billion-dollar question.
Hayden EC
Nature; 2008 May; 453(7191):18-21. PubMed ID: 18461716
[No Abstract] [Full Text] [Related]
15. Industry highlights: Stem cell and regenerative medicine.
Ilic D
Regen Med; 2011 Nov; 6(6 Suppl):55-60. PubMed ID: 21999262
[No Abstract] [Full Text] [Related]
16. Chemical control of stem cell fate and developmental potential.
Lyssiotis CA; Lairson LL; Boitano AE; Wurdak H; Zhu S; Schultz PG
Angew Chem Int Ed Engl; 2011 Jan; 50(1):200-42. PubMed ID: 21184400
[TBL] [Abstract][Full Text] [Related]
17. Intellectual property strategy for regenerative medicine: is it time to 'regenerate'?
Komatani TS
Pharm Pat Anal; 2014 Sep; 3(5):475-9. PubMed ID: 25374315
[No Abstract] [Full Text] [Related]
18. Industry updates from the field of stem cell research and regenerative medicine in March 2020.
Ilic D; Liovic M
Regen Med; 2020 Jul; 15(7):1833-1840. PubMed ID: 32452720
[TBL] [Abstract][Full Text] [Related]
19. Stem cells: The impatient advocate.
Dolgin E
Nature; 2010 Dec; 468(7324):620-3. PubMed ID: 21124428
[No Abstract] [Full Text] [Related]
20. The international translational regenerative medicine center.
Alexis Mde V; Grinnemo KH; Jove R
Regen Med; 2012 Nov; 7(6 Suppl):74-5. PubMed ID: 23210815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
